Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference

HOUSTON, TX--(Marketwired - April 26, 2018) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that Dr. Waldemar Priebe, Chair of the Company's Scientific Advisory Board, has been selected to present findings on Moleculin's STAT3 inhibitor and immuno-stimulating agent, WP1066, at the Global Academic Programs 2018 in Stockholm, Sweden in May of this year.

The Global Academic Programs ("GAP") 2018 is being hosted in Stockholm, Sweden from May 15 to 17, 2018. The annual GAP Conference provides a forum for faculty from MD Anderson and its Sister Institutions to develop collaborations and exchange research results and ideas. Sessions are formed around topics of interest to the members of the Sister Institution Network. The GAP 2018 Conference is being sponsored by a prestigious list of major pharmaceutical companies, including Roche, Bayer, Bristol-Meyers Squibb, AstraZeneca, Novartis, Merck and Pfizer.

"We are eager to share our important findings with regard to WP1066 and its effects on pancreatic cancer that include the ability to suppress activation of STAT3 in vitro and in vivo and simultaneously producing strong anticancer effects in this most deadly type of cancer," commented Dr. Waldemar Priebe, Chair of Moleculin's Scientific Advisory Board. "In addition to pancreatic cancer, WP1066 appears to produce significant anticancer effects in animal models of other difficult to treat tumors, including brain cancers like glioblastoma. Moleculin has already announced an approved IND for brain tumors. We hope our continuation of the in vivo evaluation of WP1066 in different tumor models will provide a strong basis for the initiation of additional clinical trials in the future."

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.